Royalty Pharma plc (NASDAQ:RPRX) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma Third Quarter Earnings Conference Call.
Royalty Pharma Plc (RPRX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 11,965,633 | $422,147,532 | +100% | 0.67% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,282,174 | $115,795,099 | +11% | 0.07% |
| 3. | Patient Capital Management Samantha Mclemore | 3,117,850 | $109,997,741 | +5% | 4.4% |
| 4. | Millennium Management Israel Englander | 2,235,133 | $78,855,492 | +380% | 0.03% |
| 5. | AQR Capital Management Cliff Asness | 1,961,086 | $69,187,107 | +13% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.51 | 130,000 | $3,836,768.00 | 600,000 | 2023-06-28 | Filing | |
| $32.78 | 45,000 | $1,474,902.00 | 470,000 | 2023-06-13 | Filing | |
| $33.00 | 45,000 | $1,484,946.00 | 425,000 | 2023-06-12 | Filing | |
| $32.25 | 150,000 | $4,837,440.00 | 380,000 | 2023-05-24 | Filing | |
| $32.94 | 69,612 | $2,293,095.85 | 230,000 | 2023-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.38 | 20,000 | $767,582.00 | 120,000 | 2025-12-19 | Filing | |
| $38.50 | 30,654 | $1,180,053.32 | 0 | 2025-12-18 | Filing | |
| $38.57 | 79,346 | $3,060,280.00 | 30,654 | 2025-12-17 | Filing | |
| $38.32 | 20,000 | $766,420.00 | 140,000 | 2025-12-16 | Filing | |
| $38.36 | 3,750 | $143,850.38 | 43,510 | 2025-12-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 44,163,954 | $1,558,104,371 | 0.09% | |
| 2. | 27,986,714 | $987,371,261 | 0.05% | |
| 3. | 27,212,694 | $960,063,844 | 0.15% | |
| 4. | 26,200,503 | $924,353,737 | 0.02% | |
| 5. | 17,372,502 | $612,901,870 | 0.45% |
News See All
What Do Analysts Think About Royalty Pharma Plc (RPRX)?
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most profitable biotech stocks to buy.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth
Royalty Pharma plc (NASDAQ:RPRX), a leader in biopharma royalties, made major strategic moves in September 2025.
10 Best Pharma Stocks to Buy According to Billionaires
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United States down to "most favored...
TD Cowen Maintains a Buy on Royalty Pharma (RPRX)
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best affordable biotech stocks to invest in now. On September 12, TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Royalty Pharma Plc (NASDAQ...
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts
Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing in acquiring and managing royalties from marketed drugs, continues to demonstrate strong growth and strategic expansion.
12 Cheap Healthcare Stocks to Buy Now
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there are any opportunities ...
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program
Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of the best performing stocks.
Hedge Fund Resource Center Billionaire Hedge Funds
